Pharming « Terug naar discussie overzicht

quote:

RRR schreef op 8 aug 2012 om 19:35:

Why Santarus' Shares Plunged

By Sean Williams , The Motley Fool
Posted 12:44PM 08/08/12
Posted under: Investing
-
-
-
-
-
-
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of specialty biotechnology firm Santarus (NAS: SNTS) have had a wild ride today with its shares losing as much as 34% earlier this morning after reporting its second-quarter earnings results.
So what: For the quarter, Santarus reported a 77% increase in revenue to $47.2 million while net income grew 27% to $3.4 million, or $0.05 per share. Unfortunately, Santarus' profits fell $0.03 shy of what Wall Street had expected despite the robust growth. Santarus' guidance calls for the company to hit about $200 million in revenue in fiscal 2012, which is in line with the Street's forecast, and net income of $8 million to $11 million, or what amounts to $0.13 to $0.18 in EPS, more or less in line with analysts' current range of $0.15 to $0.18.

Now what: it's still early in the game, but Santarus showed remarkable growth for its three commercial drugs. Diet-control drugs Glumetza and Cycloset, targeted at type 2 diabetes patients, saw total prescriptions increase by 34% and 100%, respectively, while Fenoglide, which assists in cholesterol reduction, had growth of 17% in total prescriptions. In addition to these commercial drugs, Santarus submitted a new drug application for its ulcerative colitis drug, Uceris, and has multiple other clinical phase trials under way. Personally, I see today's earnings miss and drop as an overreaction and would take a much closer look at Santarus as a potential buy.


-------


De nadruk zal bij hen niet liggen op overname nu (vermoeden)

quote:

RRR schreef op 20 sep 2012 om 09:36:

seekingalpha.com/article/877211-santa...


We expect to announce results from the Phase III study in the end of October or first half of November.

quote:

RRR schreef op 20 sep 2012 om 09:36:

seekingalpha.com/article/877211-santa...


We expect to announce results from the Phase III study in the end of October or first half of November.

quote:

RRR schreef op 20 sep 2012 om 10:00:

Ruconest is our second product. It actually will read out late October, early November. It’s a recombinant C1 inhibitor for hereditary angioedema. Two studies have already been completed. This is a third study, 75 patients. It’s a three to two design, 45 patients on active, 30 on placebo. We think this will be a best-in-class product. It’s a recombinant C1 inhibitor, two [plasma-derived] products, Cinryze and Berinert.

We think recombinant products, by virtue of being recombinant, are safer products for patients. And we think it will be the most effective product. We do have a patent on this product. It will have an orphan drug, seven years exclusivity. It will also fall underneath the biologics, with 12 years of exclusivity.

These are the two Phase III studies that were completed. The European study had 100 units per kilogram. The U.S. study, 100 units and 50. The current studies have 50 units per kilogram. You can see on the right, very highly statistically significant results.

The marketplace is evolving. Cinryze is the first product approved. They’ll do somewhere around $300 million. As more products have been approved for acute use, you’re seeing the movement over in that direction. Also, you’re seeing more patients on steroids move over into acute treatment. We expect that will continue to happen.

We also expect more patients will actually seek treatment, and they’ll treat more of their attacks on an ongoing basis. Currently it’s estimated at about a $400 million marketplace. We expect it will be about a $600 million to $800 million market. <---speciaal voor kammetje... :-)

quote:

Beur schreef op 20 sep 2012 om 10:32:

Vergeet a.u.b. niet dat van die 600-800$ miljoen market in 2012 al ruim 400 miljoen is ingepikt door de concurrentie!!
En dat Rhucin ook in 2013 nog niet op de USA-markt zal zijn....